BTK
BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 167 products of "BTK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Formula:C25H23ClN4O4Purity:98.68% - 99.63%Color and Shape:SolidMolecular weight:478.93Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Formula:C26H25N3O3Purity:97.77% - 99.54%Color and Shape:SolidMolecular weight:427.49Ref: TM-T12317
1mg86.00€5mg177.00€1mL*10mM (DMSO)205.00€10mg299.00€25mg492.00€50mg682.00€100mg897.00€500mg1,791.00€IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formula:C22H22N6OPurity:99.8% - 99.88%Color and Shape:SolidMolecular weight:386.45Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Formula:C25H23ClN6O3Purity:99.27% - 99.95%Color and Shape:SolidMolecular weight:490.94Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Formula:C24H25N5O3Purity:99.94%Color and Shape:SolidMolecular weight:431.49Ref: TM-T10629
1mg34.00€2mg49.00€5mg74.00€1mL*10mM (DMSO)82.00€10mg98.00€25mg215.00€50mg356.00€100mg434.00€Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Formula:C36H40FN9O3Purity:98.28% - 99.76%Color and Shape:SolidMolecular weight:665.76Ref: TM-T12542
1mg94.00€5mg222.00€1mL*10mM (DMSO)325.00€10mg356.00€25mg620.00€50mg893.00€100mg1,251.00€500mg2,502.00€MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Formula:C41H41N9O8Purity:95.93% - 97%Color and Shape:SolidMolecular weight:787.82Ref: TM-T16157
1mg92.00€5mg177.00€1mL*10mM (DMSO)231.00€10mg269.00€25mg510.00€50mg692.00€100mg888.00€200mg1,251.00€AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Formula:C33H31FN6O3Purity:≥95%Color and Shape:SolidMolecular weight:578.64DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formula:C55H62N10O8Color and Shape:SolidMolecular weight:991.163FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Color and Shape:LiquidPROTAC BTK Degrader-10
CAS:PROTAC BTK Degrader-10 (Example 1P) is a PROTAC compound that targets BTK for degradation. It is applicable in the research of chronic lymphocytic leukemia (CLL). [Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase Cereblon].Formula:C42H49N11O4Color and Shape:SolidMolecular weight:771.91PROTAC BTK Degrader-13
PROTAC BTK Degrader-13 (Compound 25) is a targeted BTK PROTAC degrader with a DC50 of 0.27 μM. It inhibits BTK activity with an IC50 of 0.44 μM and suppresses IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. This compound also inhibits the p38 MAPK signaling pathway, thereby blocking the activation of the BCR (B cell receptor) signaling pathway. [Pink: ligand for target protein BTK ligand 15; Black: linker; Blue: ligand for E3 ligase cereblon]Formula:C33H30N6O7Color and Shape:SolidMolecular weight:622.63PROTAC BTK Degrader-11
CAS:PROTAC BTK Degrader-11 is a PROTAC degrader that targets and degrades BTK with a DC50 of 1.7 nM. It is utilized in oncological research.Formula:C48H55N11O4Color and Shape:SolidMolecular weight:850.02BTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formula:C25H24F3N7O3Color and Shape:SolidMolecular weight:527.508PROTAC BTK Degrader-5
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity byFormula:C52H57ClFN9O6Purity:98%Color and Shape:SolidMolecular weight:958.52Atuzabrutinib
CAS:Atuzabrutinib (SAR 444727) is a selective BTK inhibitor and can be used to study arthritis in rheumatoid rodents and pemphigus vulgaris.Formula:C30H30FN7O2Purity:97.27% - 99.38%Color and Shape:SolidMolecular weight:539.6Ref: TM-T39056
1mg69.00€5mg147.00€1mL*10mM (DMSO)170.00€10mg224.00€25mg358.00€50mg512.00€100mg707.00€200mg973.00€L18I
L18I is a PROTAC (Proteolysis Targeting Chimera) that targets Btk to mitigate inflammation in autoimmune diseases. The components of L18I include the PROTAC target protein ligand IBT6A, the PROTAC linker Propargyl-PEG3-alcohol, and the E3 ubiquitin ligase ligand Lenalidomide-Br. Notably, the active control for the target protein ligand is IBT6A-CO-ethyne, while the conjugate of the E3 ubiquitin ligase ligand with the linker is Lenalidomide-C3-PEG3-N3.Formula:C47H51N11O8Color and Shape:SolidMolecular weight:897.98BTK-IN-40
CAS:BTK-IN-40 (compound 375) is an inhibitor of BTK.Formula:C20H25N7O2Color and Shape:SolidMolecular weight:395.46PROTAC BTK Degrader-6
CAS:PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expressionFormula:C45H47N11O6Purity:98%Color and Shape:SolidMolecular weight:837.92BTK inhibitor 17
CAS:BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.Formula:C25H24N6O3Purity:99.57% - 99.88%Color and Shape:SolidMolecular weight:456.5Ref: TM-T9706
1mg89.00€5mg166.00€1mL*10mM (DMSO)166.00€10mg250.00€25mg403.00€50mg532.00€100mg745.00€200mg982.00€DCAF1 binder 2
DCAF1 Binder 2, an E3 ligase ligand, is implicated in BRD9, kinase, and selective Bruton's tyrosine kinase (BTK) degradation.Color and Shape:Odour SolidPCI-33380
CAS:PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.Formula:C46H52BF2N11O3Purity:98%Color and Shape:SolidMolecular weight:855.8BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formula:C23H23ClFN7O2Color and Shape:SolidMolecular weight:483.93evobrutinib
CAS:Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in theFormula:C25H27N5O2Purity:98.03% - 99.58%Color and Shape:SolidMolecular weight:429.51Ref: TM-T4387
1mg42.00€1mL*10mM (DMSO)87.00€5mg88.00€10mg127.00€25mg227.00€50mg329.00€100mg472.00€500mg1,017.00€GBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formula:C44H47N9O6Purity:98%Color and Shape:SolidMolecular weight:797.9BTK-IN-5
CAS:BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Formula:C23H32N4O5Color and Shape:SolidMolecular weight:444.532BIIB091
CAS:BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.Formula:C28H34N10O2Color and Shape:SolidMolecular weight:542.648Ibrutinib dimer
CAS:Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Formula:C50H48N12O4Purity:98%Color and Shape:SolidMolecular weight:880.99Acalabrutinib enantiomer
CAS:R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.
Formula:C26H23N7O2Purity:97.27%Color and Shape:SolidMolecular weight:465.51PROTAC BTK Degrader-12
CAS:PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.Formula:C47H54N12O4Color and Shape:SolidMolecular weight:851.01FDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Color and Shape:Odour SolidNRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Formula:C43H51N11O6Color and Shape:SolidMolecular weight:817.94CNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Formula:C48H68N10O9SPurity:98%Color and Shape:SolidMolecular weight:961.18PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Formula:C47H54F2N8O13Color and Shape:SolidMolecular weight:976.97Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Formula:C8H6BrN3SPurity:99.94%Color and Shape:SolidMolecular weight:256.12BCPyr
CAS:BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formula:C58H65F2N11O8Color and Shape:SolidMolecular weight:1082.224QL-X-138 HCl
QL-X-138 HCl is a BTK/MNK dual kinase inhibitor with anticancer activity and anti-dengue virus 2 activity that inhibits BTK, MNK1, and MNK2 kinases.Formula:C25H20ClN5O2Purity:99.25%Color and Shape:SoildMolecular weight:457.91BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Color and Shape:Odour SolidI-As-1
I-As-1 is a potent inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 2.35 nM. It exhibits antiproliferative activity against Ramos cells and OCI-LY10 cells, with IC50 values of 0.52 μM and 0.11 μM, respectively.Formula:C26H27AsN6O2S2Molecular weight:594.08529PROTAC BTK Degrader-9
PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.Formula:C46H52FN13O5Molecular weight:885.41984DBt-10
DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].Formula:C68H86ClFN16O6Purity:98%Color and Shape:SolidMolecular weight:1277.96SJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formula:C41H45ClN8O7Purity:98%Color and Shape:SolidMolecular weight:797.3PROTAC BTK Degrader-8
PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.Formula:C80H94F2N14O20P2Molecular weight:1670.62121PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Formula:C43H43N9O4Color and Shape:SolidMolecular weight:749.86Ibrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Formula:C56H80N12O9SPurity:98%Color and Shape:SolidMolecular weight:1097.39TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Color and Shape:Odour SolidPoseltinib
CAS:Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.Formula:C26H26N6O3Purity:99.98%Color and Shape:SolidMolecular weight:470.52Ref: TM-T4413
2mg34.00€5mg49.00€1mL*10mM (DMSO)50.00€10mg75.00€25mg146.00€50mg260.00€100mg409.00€200mg590.00€Anti-BTK Antibody (3G585)
Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.Color and Shape:Odour LiquidIBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Formula:C22H23ClN6OColor and Shape:SolidMolecular weight:422.91Elsubrutinib
CAS:Elsubrutinib (ABBV-105) is an orally active, selective, and irreversible BTK inhibitor with an IC50 of 0.18 μM for the catalytic domain of BTK.Formula:C17H19N3O2Purity:99.77%Color and Shape:SolidMolecular weight:297.36Ref: TM-T39130
1mg145.00€5mg250.00€10mg340.00€1mL*10mM (DMSO)356.00€25mg573.00€50mg879.00€100mg1,314.00€
